Chief Executive Officer
Joshua Grass, Chief Executive Officer, joined Escient in December 2021. Most recently, Josh was Chief Executive Officer from 2017 to 2019 of Modis Therapeutics, a company developing a treatment for a rare mitochondrial disease. As an Entrepreneur in Residence at F-Prime Capital, Josh led a $30M series A financing (F-Prime Capital and Orbimed Advisors) of ModisTx in March of 2018. ModisTx was acquired by Zogenix for $400M in total consideration ($250M upfront) in September of 2019. From 2002 to 2017 Josh was a member of the BioMarin senior executive management team, during most of that time leading Business and Corporate Development reporting to the CEO. Over these 15 years at BioMarin, Josh led the acquisition and divestiture of many technologies and products, and also participated in the global development and launch of many products to treat rare genetic diseases. Josh started his career in biotech as a scientist at Cerus corporation from 1993 to 1998 after which time held roles in finance and equity research at boutique investment banks. Josh earned a B.S in Biology from California Polytechnic State University, San Luis Obispo and an MBA in Finance and Entrepreneurship from William E. Simon School of Business at the University of Rochester.